Thursday, 8 October 2026
Australia’s polypharmacy burden, Dark-web therapeutic goods surveillance, Solengepras Parkinson’s trial results
- 01
Polypharmacy affects 1.9 million Australians, national estimate finds
Around 1.9 million Australians, or 7% of the population, were taking five or more medicines, according to the AIHW’s first national estimate using 2025 PBS and RPBS data. Prevalence rose from around 20% among people aged 65–74 to around 40% among those aged 75 and over, while about one in nine people with polypharmacy regularly received 10 or more medicines. Rates were similar among men and women, and medicine patterns shifted from antidepressants, antipsychotics and psychostimulants in younger people towards treatments for chronic conditions in older groups. The AIHW said the number of people exposed to multiple medicines was likely to increase as the population ages and plans further reports to track prevalence over time and geographical variation. Because private prescriptions were excluded, the agency said the findings may underestimate the true extent of polypharmacy in Australia.
via RACGP newsGP · also covered by The Medical Republic
- 02
TGA deploys dark-web tools against illegal therapeutic goods
The TGA has equipped investigators with software capable of dark-web searches, AI-driven analysis and secure persona-based investigations to strengthen surveillance of therapeutic goods sold and promoted illegally online. Freedom of information documents showed the regulator spent $107,250 on three 12-month licences for Fivecast Onyx Pro, covering 1 July 2025 to 30 June 2026. The platform can analyse deep-web sources, social media and other online information as the TGA faces increasingly numerous and complex tip-offs and referrals about potentially unlawful activity. The regulator is particularly concerned about the online promotion and sale of unapproved therapeutic goods, which can pose health risks, while prescription-only medicines cannot legally be advertised to the public. The TGA declined to detail its investigative methods or information-handling arrangements, citing operational concerns and broader departmental governance requirements.
- 03
Solengepras reduced Parkinson’s off time in late-stage trial
The higher dose of solengepras significantly reduced daily “off” time in a late-stage trial of people with Parkinson’s disease who continued to experience motor fluctuations despite levodopa and other drugs. The trial randomised 341 participants to placebo or one of two once-daily doses, with the higher dose reducing average daily off time by 0.61 hours versus placebo after 12 weeks. It also increased “on” time without troublesome dyskinesia by 0.60 hours compared with placebo, narrowly reaching statistical significance. Cerevance said the non-dopaminergic drug was generally well tolerated, with no serious adverse events reported in the higher-dose group; the company plans to discuss next steps with the US Food and Drug Administration.
via BioPharma Dive
- 04
UK bans first adverts for unlicensed oral GLP-1 products
UK regulators banned advertisements for oral weight-loss drugs for the first time after two online pharmacies promoted unlicensed, prescription-only medicines to the public. The Advertising Standards Authority found that paid social media advertisements and website content promoted oral GLP-1 products by inviting people to join waiting lists, register interest and pre-order treatment. It said Simple Online Pharmacy advertised the treatments before any GLP-1 medicine had been authorised in the UK. UK advertising rules require medicines to have Medicines and Healthcare Products Regulatory Agency authorisation before promotion and prohibit medicinal claims for unauthorised treatments; the source gives limited detail about the second pharmacy’s advertisements.
via BMJ
- 05
FDA approves patient-facing updates to Abbott’s CardioMEMS system
The FDA approved updates to Abbott’s CardioMEMS heart failure monitoring system that will let patients view their pulmonary artery pressure readings for the first time. The implanted sensor measures pressure in the pulmonary artery to detect worsening heart failure before symptoms appear. A new dynamic treatment plan feature will allow clinicians to adjust medications based on pressure changes and send personalised instructions directly to patients through the CardioGuide HF smartphone app. Abbott expects to make the app and dynamic treatment plans available later this year.
via MedTech Dive
- 06
WHO assesses plague epidemic risk as low after Russian death
The risk of a plague epidemic is low after the death of a technician at a Russian plague research institute, WHO said. WHO is closely monitoring the situation and urged Russian authorities to be transparent about the death. Darya Shipilova, 28, died on 2 October after Russian authorities described her illness as pneumonia of unknown aetiology, while media reports suggested pneumonic plague and a possible laboratory accident. Quarantine measures have been introduced at the Irkutsk research centre and several regional hospitals.
via BMJ
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.